NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares NLS Pharmaceutics (NASDAQ: NLSP / NLSPW) and Kadimastem (TASE: KDST) announced that all material conditions precedent for their merger have been satisfied or waived, and the merger closing is set for October 30, 2025. Nasdaq approved listing of the combined company's common shares.The combined company will be named NewCelX Ltd. and listed on the Nasdaq Capital Market under the ticker NCEL beginning October 31, 2025. Kadimastem trading on TASE will be suspended and its final delisting is scheduled for October 31, 2025.The final exchange ratio is 7.06 NLS common shares per Kadimastem share, which after a 1-for-10 reverse split of NLS shares becomes 0.706 NLS common shares per Kadimastem share. NewCelX shares are expected to be deposited to Kadimastem shareholders' accounts by the end of day November 3, 2025, with trading availability expected November 4, 2025 or soon thereafter.

#NLSP #NLSPW #KMSTF NLS Pharmaceutics and Kadimastem Announce Completion of Material Conditions Precedent for Merger Transaction and Delisting Date of Kadimastem's Shares

www.stocktitan.net/news/NLSP/nls-pharmaceut...

706,000 Hong Kong Diabetes Patients: NLS Pharma Secures Critical Patent for Revolutionary Cell Therapy Patent covers cell selection technology for IsletRx diabetes treatment, expanding protection in Asia. Hong Kong's diabetes market represents $90B opportunity with 8.2% adult prevalence.

#NLSP #KMSTF NLS Pharmaceutics and Kadimastem announce a Hong Kong Patent Covering Cell-Selection and Enrichment Technology for IsletRx for Diabetes Patients

www.stocktitan.net/news/NLSP/nls-pharmaceut...

NLS Pharmaceutics Transforms: $25M Backing Powers Merger Deal as Company Goes Debt-Free Latest shareholder letter reveals debt-free status, $25M financing facility, and merger timeline for Q3 2025. See how NewcelX will reshape CNS and diabetes treatment landscape.

#NLSP #KMSTF NLS Pharmaceutics CEO Issues Letter to Shareholders

www.stocktitan.net/news/NLSP/nls-pharmaceut...

Game-Changing Drug Shows Success in Blocking Fentanyl's Addictive Effects Novel drug Mazindol demonstrates significant reduction in fentanyl reward behavior in preclinical study. Breakthrough findings reveal multiple mechanisms of action. Full analysis inside.

#NLSP #KMSTF #NLSPW NLS Pharmaceutics Announces Positive Results from Study KO-943 Demonstrating Mazindol Reduces Fentanyl-Induced Reward in Animal Models

www.stocktitan.net/news/NLSP/nls-pharmaceut...

Game-Changing Drug Could End Fentanyl Epidemic: NLS Pharma's Bold Move NLS Pharmaceutics launches Mazindol ER preclinical program to combat fentanyl dependence amid rising overdose deaths. Patent-protected until 2038, offering new hope beyond traditional treatments.

#NLSP #KMSTF #NLSPW NLS Pharmaceutics Announces the Launch of a Preclinical Program for Mazindol ER in the Treatment of Fentanyl Dependence

www.stocktitan.net/news/NLSP/nls-pharmaceut...

Kadimastem Advances NLS Pharma Merger with $500K Funding at 48% Premium, Sets Key Vote Kadimastem schedules shareholder vote for NLS merger following $500K funding at $3.10/share. Combined Nasdaq entity to focus on CNS disorders and cell therapy solutions.

#NLSP #KMSTF Kadimastem Calls for a Special General Meeting of Shareholders to Approve the Merger with NLS

www.stocktitan.net/news/NLSP/kadimastem-cal...